Novartis to acquire Tourmaline Bio for $1.4bn.

Novartis, a Swiss multinational pharmaceutical company, offered to acquire Tourmaline Bio, a New York-based clinical-stage biopharmaceutical company, for $1.4bn. "Inflammation is a major driver of cardiovascular disease, and the team at Tourmaline has made significant progress with this asset. We are excited to bring pacibekitug into the Novartis portfolio and collaborate with the Tourmaline team to advance its development as we diversify our efforts in cardiovascular care," Shreeram Aradhye, Novartis President, Development and Chief Medical Officer.